The clinical approach states that therapy with BRAF and MEK inhibitors should be stopped in case of stage 2 hypertension, defined as systolic blood pressure more than 160 mm Hg or diastolic blood pressure more than 100 mm Hg. The gene discussed is BRAF; the disease is hypertensive disorder.